{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05775523",
            "orgStudyIdInfo": {
                "id": "ASND0033"
            },
            "organization": {
                "fullName": "Ascendis Pharma A/S",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin",
            "officialTitle": "A Prospective, Non-interventional (NIS), Long-term, Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin",
            "acronym": "SkyPASS",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-post-authorisation-safety-study-pass-of-patients-treated-with-lonapegsomatropin"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-03-20",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2033-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2033-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-03-08",
            "studyFirstSubmitQcDate": "2023-03-08",
            "studyFirstPostDateStruct": {
                "date": "2023-03-20",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-09",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-10",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Ascendis Pharma Endocrinology Division A/S",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting."
        },
        "conditionsModule": {
            "conditions": [
                "Growth Hormone Deficiency"
            ],
            "keywords": [
                "Human Growth Hormone",
                "hGH",
                "rhGH",
                "GHD",
                "Long Acting Growth Hormone",
                "Lonapegsomatropin",
                "Prodrug",
                "Growth Failure",
                "Growth Hormone Replacement Therapy",
                "Sustained Release Growth Hormone",
                "Growth Hormone Deficiency",
                "TransCon hGH",
                "Skytrofa",
                "SkyPASS"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 500,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Patients on SKYTROFA (Lonapegsomatropin)Treatment",
                    "description": "SKYTROFA (Lonapegsomatropin) administered once-weekly by subcutaneous injection",
                    "interventionNames": [
                        "Drug: No intervention"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "No intervention",
                    "description": "No intervention",
                    "armGroupLabels": [
                        "Patients on SKYTROFA (Lonapegsomatropin)Treatment"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Occurrence of neoplasms (benign, malignant and unspecified)",
                    "timeFrame": "5 years"
                },
                {
                    "measure": "Occurrence of type 2 diabetes mellitus",
                    "timeFrame": "5 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Occurrence of renal, hepatic, immunologic and neurologic adverse events",
                    "timeFrame": "5 years"
                },
                {
                    "measure": "Occurrence of medication errors in patients treated with lonapegsomatropin",
                    "description": "Frequency and type of medication errors as reported by treating physician",
                    "timeFrame": "5 years"
                },
                {
                    "measure": "Insulin-like Growth Factor-1 (IGF-1) response to lonapegsomatropin therapy",
                    "description": "IGF-1 level (ng/mL)",
                    "timeFrame": "5 years"
                },
                {
                    "measure": "Insulin-like Growth Factor-1 (IGF-1) response to lonapegsomatropin therapy",
                    "description": "IGF-1 Standard Deviation Score (SDS)",
                    "timeFrame": "5 years"
                },
                {
                    "measure": "Compare the occurrence of neoplasms (benign, malignant and unspecified) in patients treated with lonapegsomatropin with historical data from literature",
                    "timeFrame": "5 years"
                },
                {
                    "measure": "Compare the occurrence of type 2 diabetes mellitus in patients treated with lonapegsomatropin with historical data from literature",
                    "timeFrame": "5 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Paediatric patients with GHD who are on treatment with lonapegsomatropin\n* Patients being clinically managed in Europe or the USA\n* Appropriate written informed consent/assent as applicable for the age of the patient\n* Patients willing to comply with follow-up requirements of the study\n\nExclusion Criteria:\n\n* Patients participating in any interventional clinical trial for short stature\n* Patients being treated with a GH or IGF-1 therapy, other than lonapegsomatropin, at enrollment\n* Patients for whom treatment with lonapegsomatropin is contraindicated\n* Patients with closed epiphyses\n* Patients with active malignant tumours\n* Patients under antitumour therapy within the past 12 months prior to instituting GH therapy\n* Hypersensitivity to somatropin or any of the excipients in lonapegsomatropin",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "1 Year",
            "maximumAge": "18 Years",
            "stdAges": [
                "CHILD",
                "ADULT"
            ],
            "studyPopulation": "Patients from centres in Europe and the USA will be eligible for enrollment into the study.\n\nPatients may be enrolled in the study if they are on treatment with lonapegsomatropin. The decision to treat the patient with lonapegsomatropin will be made prior to and independently of the decision to invite the patient to enroll into the study. Both patients na\u00efve to GH treatment and patients previously treated with GH therapy will be eligible for enrollment.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Mandeep Singh",
                    "role": "CONTACT",
                    "phone": "+1 650-505-4946",
                    "email": "msh@ascendispharma.com"
                }
            ],
            "locations": [
                {
                    "facility": "Ascendis Pharma Investigational Site",
                    "status": "RECRUITING",
                    "city": "Centennial",
                    "state": "Colorado",
                    "zip": "80112",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.57916,
                        "lon": -104.87692
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M8326",
                    "name": "Failure to Thrive",
                    "relevance": "LOW"
                },
                {
                    "id": "T2633",
                    "name": "Growth Hormone Deficiency",
                    "asFound": "Growth Hormone Deficiency",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3125",
                    "name": "Isolated Growth Hormone Deficiency",
                    "asFound": "Growth Hormone Deficiency",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}